Genetics, Inc. (Nasdaq: SGEN) announced today that it has submitted
a supplemental Biologics License Application (BLA) to the U.S. Food and
Drug Administration (FDA) based on data from the phase 3 AETHERA trial
of ADCETRIS (brentuximab vedotin) as consolidation therapy immediately
following an autologous stem cell transplant (ASCT) in Hodgkin lymphoma
(HL) patients at high risk of relapse.
for Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at High Risk of Relapse investment picks